长春高新(000661.SZ)：子公司GS3-007a干混悬剂境内生产药品注册临床试验申请获得批准

Core Viewpoint - Changchun High-tech (000661.SZ) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the clinical trial of GS3-007a, a drug aimed at treating pediatric growth hormone deficiency [1] Group 1 - Changchun Jinsai Pharmaceutical has developed GS3-007a, an oral small molecule growth hormone secretagogue [1] - The drug is classified as a Class 1 chemical drug and is intended for the treatment of pediatric growth hormone deficiency (PGHD) [1] - The approval marks a significant milestone for the company in advancing its product pipeline [1]